Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative

Aptevo Therapeutics Inc.

100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.
Two patients achieved complete remission with MRD-negative status, including one with TP53 mutation.
Results build on prior trial where 100% of frontline patients also achieved remission.
Mipletamig continues to show favorable safety and tolerability profile; Cohort 2 enrollment commencing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.